Lexon must pay £1.2m as CMA nortriptyline probe upheld

[helvella]

This story is, as it stands, off-topic. But the CMA case regarding liothyronine continues. I would say "apace", but it is rather more "abed" as in it feels as if everyone involved has gone to sleep.

Nonetheless, a CMA win is possibly marginally good news from our perspective.

Lexon must pay £1.2m as CMA nortriptyline probe upheld

by Valeria Fiore 25/02/2021 0 comments News

Lexon was accused, along with two other wholesalers, of colluding to keep nortriptyline prices up

The Competition Appeal Tribunal (CAT) has dismissed Lexon (UK)’s appeal of a CMA fine and investigation, which said the company broke the law over the supply of nortriptyline.

Through an investigation carried out last year, the Competition and Markets Authority (CMA) concluded that King Pharmaceuticals, Auden Mckenzie, Lexon (UK) and Alissa Healthcare broke the law in relation to the supply of nortriptyline, a drug that is used to relieve the symptoms of depression.

chemistanddruggist.co.uk/ne...

[jsy_girl]

Very interesting thanks for sharing

[Rapunzel]

I would say "apace", but it is rather more "abed" as in it feels as if everyone involved has gone to sleep.

Matches the condition then, innit tho x

[Bearo]

Thanks for this. So is this similar to the T3 situation or are there differences that would make it harder to bring a case? What are the main stumbling blocks that are allowing T3 to be so expensive?

[helvella Administrator in reply to Bearo]

One problem is the way the companies have insisted that it is because the MHRA imposes higher standards than they do in Germany, France, Greece, Italy.

Without access (and ability to understand) the actual documents, etc., I certainly cannot don't know if there is any truth at all. But seems very odd if Germany in particular has lower standards. And we accept Teva and Aristo levothyroxine from abroad without any obvious problem.

Other than that, perhaps the companies can afford better lawyers?

[Bearo]

Thanks